倾向性评分匹配方案：特拉唑嗪联合非那雄胺治疗良性前列腺增生——性激素与控尿效果
A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia - Sex Hormone And Urinary Control Effects.
摘要(中文译文)
探讨盐酸特拉唑嗪联合非那雄胺治疗良性前列腺增生（BPH）的临床疗效，并分析其对性激素及控尿功能的影响。本回顾性倾向性评分匹配（PSM）队列研究纳入2020年1月至2021年3月期间接受治疗的BPH患者。采用logistic回归进行1：1 PSM，预设协变量包括年龄、BMI、IPSS、Qmax、PVR、PV、PSA、CRP、T、E2、DHT、尿失禁发作次数、ICIQ-SF；纳入标准为年龄50~80岁、IPSS≥8、PSA>1.4 ng/mL、PV≥40 mL、Qmax≤15 mL/s；排除既往接受过前列腺手术或使用过5α-还原酶抑制剂/α1受体阻滞剂者；治疗12个月，随访36个月，于6、12、24、36个月时测量结局指标。经PSM后每组各纳入60例患者。联合治疗组在IPSS、Qmax、PVR及PV方面改善均显著更优（均P<0.05），DHT及E2水平更低，T水平更高（均P<0.05），24小时尿失禁发作次数更少，ICIQ-SF评分更优（均P<0.05）。两组安全性特征相当（P>0.05）。特拉唑嗪-非那雄胺方案与更好的长期结局、更优的控尿功能及有利的激素变化相关，但激素效应主要归因于非那雄胺。
Abstract
To investigate the clinical effect of terazosin hydrochloride combined with finasteride in benign prostatic hyperplasia (BPH), and to analyze its effect on sex hormones and urinary control. This retrospective propensity score‑matched (PSM) cohort study included BPH patients treated between January 2020 and March 2021. 1:1 PSM using logistic regression with prespecified covariates (age, BMI, IPSS, Qmax, PVR, PV, PSA, CRP, T, E2, DHT, incontinence episodes, ICIQ‑SF); inclusion criteria (age 50‑80 years, IPSS ≥ 8, PSA > 1.4 ng/mL, PV ≥ 40 mL, Qmax ≤ 15 mL/s); exclusion of prior prostate surgery or 5α‑reductase/α1‑blocker use; 12‑month treatment and 36 month follow up with outcomes measured at 6, 12, 24, 36 months. Sixty patients were allocated to each group after PSM. The combination group showed significantly greater improvements in IPSS, Qmax, PVR, and PV (all P < 0.05), lower DHT and E2, higher T (all P < 0.05), fewer 24 h incontinence episodes, and better ICIQ‑SF scores (both P < 0.05). Safety profiles were comparable (P > 0.05). The terazosin‑- finasteride regimen is associated with improved long-term outcomes, better urinary control, and favorable hormonal changes, though hormonal effects are primarily attributable to finasteride.
如何引用
AMA
Yanlei Wu, Wangjia Ma. A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia - Sex Hormone And Urinary Control Effects.. Journal of visualized experiments : JoVE. 2026; doi:10.3791/70785.
APA
Yanlei Wu, Wangjia Ma (2026). A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia - Sex Hormone And Urinary Control Effects.. Journal of visualized experiments : JoVE. https://doi.org/10.3791/70785
GB/T 7714
Yanlei Wu, Wangjia Ma. A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia - Sex Hormone And Urinary Control Effects.[J]. Journal of visualized experiments : JoVE, 2026 doi:10.3791/70785.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出